אינג'י 10 מג80 מג טבליות

Country: Իսրայել

language: եբրայերեն

source: Ministry of Health

active_ingredient:

EZETIMIBE; SIMVASTATIN

MAH:

MERCK SHARP & DOHME ISRAEL LTD

ATC_code:

C10AA01

pharmaceutical_form:

טבליה

composition:

SIMVASTATIN 80 MG; EZETIMIBE 10 MG

administration_route:

פומי

prescription_type:

מרשם נדרש

manufactured_by:

MERCK SHARP & DOHME B.V., THE NETHERLANDS

therapeutic_group:

SIMVASTATIN

therapeutic_area:

SIMVASTATIN

therapeutic_indication:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

authorization_date:

2012-04-30